Revvity Inc
(BSP:R1VT34)
R$
23.77
0 (0%)
Market Cap: 81.00 Bil
Enterprise Value: 93.46 Bil
PE Ratio: 56.19
PB Ratio: 1.79
GF Score: 65/100 Revvity Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023 / 03:40PM GMT
Release Date Price:
R$20
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst
Great. Thanks, everyone, for joining this morning. My name is Matt Sykes. I'm the life science tools and diagnostics analyst at Goldman Sachs. I have the pleasure of welcoming Max Krakowiak, the CFO of Revvity. Thank you very much, Max, for being here.
Maxwell Krakowiak
Revvity, Inc. - Senior VP & CFO
Absolutely.
Questions & Answers
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst
Maybe it would be great for you to start out kind of set the stage first to talk about the most recent results, trends you're seeing in your business. And also, there was a slight name change and everything. Maybe talk a little bit about that.
Maxwell Krakowiak
Revvity, Inc. - Senior VP & CFO
Yes, sure. So I think if we go back to the commentary we had on the first quarter call. Q1 came in, I would say, probably at the upper end of our expectations.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot